FDA approves Pfizer/Merck KGaA combo in advanced colorectal cancerThe FDA has approved a combination of Pfizer’s Braftovi and Merck KGaA’s Erbitux for a form of untreated Share XFDA approves Pfizer/Merck KGaA combo in advanced colorectal cancerhttps://pharmaphorum.com/news/fda-approves-pfizer-merck-kgaa-combo-in-advanced-colorectal-cancer/
Coronavirus pandemic delay Mylan and Pfizer’s generics mergerMylan’s merger with Pfizer’s off-patent drug business has been delayed until later this year because of the coronavirus Share XCoronavirus pandemic delay Mylan and Pfizer’s generics mergerhttps://pharmaphorum.com/news/coronavirus-pandemic-delay-mylan-and-pfizers-generics-merger/
BioNTech shares pop after coronavirus vaccine deal with PfizerAs the coronavirus pandemic spreads across the world and the pressure on health system and economies mounts, Pfizer Share XBioNTech shares pop after coronavirus vaccine deal with Pfizerhttps://pharmaphorum.com/news/biontech-shares-pop-after-coronavirus-vaccine-deal-with-pfizer/
Merck, Pfizer’s Bavencio flunks head and neck cancer trialMerck KGaA and Pfizer’s checkpoint inhibitor Bavencio has failed a phase 3 trial in head and neck cancer, Share XMerck, Pfizer’s Bavencio flunks head and neck cancer trialhttps://pharmaphorum.com/news/merck-pfizers-bavencio-flunks-head-and-neck-cancer-trial/
GSK’s Walmsley gets £2.5m pay rise after strong 2019There can’t be many people in the UK who enjoyed a £2.5 million pay rise this year – Share XGSK’s Walmsley gets £2.5m pay rise after strong 2019https://pharmaphorum.com/news/gsks-walmsley-gets-2-5m-pay-rise-after-strong-sales/
The future of real world evidenceIncreasing interest in real-world evidence (RWE) across all stakeholder groups has the industry buzzing about its current role Share XThe future of real world evidencehttps://pharmaphorum.com/r-d/views-analysis-r-d/future-real-world-evidence-rwe/
FDA starts review of Pfizer, Lilly’s non-opioid painkillerAfter years in development, the FDA has started its review of Pfizer and Eli Lilly’s new painkiller tanezumab, Share XFDA starts review of Pfizer, Lilly’s non-opioid painkillerhttps://pharmaphorum.com/news/fda-starts-review-of-pfizer-lillys-non-opioid-painkiller/
Pfizer’s EU Vyndaqel okay ‘sets up $1.5bn sales next year’Pfizer’s Vyndaqel has become the first drug to be approved for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) in Europe, Share XPfizer’s EU Vyndaqel okay ‘sets up $1.5bn sales next year’https://pharmaphorum.com/news/pfizers-eu-vyndaqel-okay-sets-up-1-5bn-sales-next-year/
BMS builds case for long-term use of Opdivo in kidney cancerBristol-Myers Squibb has unveiled long-term results from its immunotherapy Opdivo in the most common form of kidney cancer, Share XBMS builds case for long-term use of Opdivo in kidney cancerhttps://pharmaphorum.com/news/bms-builds-case-for-long-term-use-of-opdivo-in-kidney-cancer/
